Katja Deterding

5.6k total citations
119 papers, 3.3k citations indexed

About

Katja Deterding is a scholar working on Hepatology, Epidemiology and Immunology. According to data from OpenAlex, Katja Deterding has authored 119 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 111 papers in Hepatology, 101 papers in Epidemiology and 12 papers in Immunology. Recurrent topics in Katja Deterding's work include Hepatitis C virus research (107 papers), Liver Disease Diagnosis and Treatment (76 papers) and Hepatitis B Virus Studies (70 papers). Katja Deterding is often cited by papers focused on Hepatitis C virus research (107 papers), Liver Disease Diagnosis and Treatment (76 papers) and Hepatitis B Virus Studies (70 papers). Katja Deterding collaborates with scholars based in Germany, United States and Netherlands. Katja Deterding's co-authors include Heiner Wedemeyer, Markus Cornberg, Michael P. Manns, Kerstin Port, Jerzy Jaroszewicz, Julia Hengst, Birgit Bremer, R. Raupach, C.–Thomas Bock and Benjamin Maasoumy and has published in prestigious journals such as Nature Communications, Hepatology and Clinical Infectious Diseases.

In The Last Decade

Katja Deterding

112 papers receiving 3.2k citations

Peers

Countries citing papers authored by Katja Deterding

Since Specialization

Citations

This map shows the geographic impact of Katja Deterding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katja Deterding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katja Deterding more than expected).

Fields of papers citing papers by Katja Deterding

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katja Deterding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katja Deterding. The network helps show where Katja Deterding may publish in the future.

Co-authorship network of co-authors of Katja Deterding

This figure shows the co-authorship network connecting the top 25 collaborators of Katja Deterding. A scholar is included among the top collaborators of Katja Deterding based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katja Deterding. Katja Deterding is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Metabolic Dysfunction–Associated Steatohepatitis Diagnosis and Management in Germany: Insights From an Expert Consensus Panel 2025 ·Liver International ·(unknown), (unknown), (unknown), (unknown), Heike Bantel, Peter Buggisch, Andreas Geier, Wolf Peter Hofmann, Stefan Mauss, Elke Roeb, Jörn M. Schattenberg, Karl‐Georg Simon, Norbert Stefan, Katja Deterding, Johannes Wiegand, Anita Pathil, Frank Tacke	3
2	Enhancing HBV-specific T cell responses through a combination of epigenetic modulation and immune checkpoint inhibition 2024 ·Hepatology ·(unknown), (unknown), Manoj Kumar Gupta, (unknown), Birgit Bremer, (unknown), Katja Deterding, Benjamin Maasoumy, Heiner Wedemeyer, Cheng‐Jian Xu, Anke Kraft, Markus Cornberg	1
3	Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis delta 2024 ·Zeitschrift für Gastroenterologie ·Mathias Jachs, Lisa Sandmann, Lukas Hartl, Tammo Lambert Tergast, Michael Schwarz, David Bauer, Lorenz Balcar, (unknown), Benedikt Hofer, Markus Cornberg, Henrike Lenzen, Katja Deterding, Michael Trauner, Mattias Mandorfer, Heiner Wedemeyer, Thomas Reiberger, Benjamin Maasoumy	4
4	Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis delta 2024 ·Journal of Hepatology ·Mathias Jachs, Lisa Sandmann, Lukas Hartl, Tammo Lambert Tergast, Michael Schwarz, David Bauer, Lorenz Balcar, (unknown), Benedikt Hofer, Markus Cornberg, Henrike Lenzen, Katja Deterding, Michael Trauner, Mattias Mandorfer, Heiner Wedemeyer, Thomas Reiberger, Benjamin Maasoumy	7
5	Limited stability of Hepatitis B virus RNA in plasma and serum 2024 ·Scientific Reports ·(unknown), Birgit Bremer, (unknown), Carola Mix, Tammo Lambert Tergast, Markus Cornberg, Heiner Wedemeyer, Katja Deterding, Benjamin Maasoumy	0
6	Die Anlage eines transjugulären intrahepatischen portosystemischen Shunts bei Patient:innen mit dekompensierter Leberzirrhose ist mit einer signifikanten Verbesserung der Lebensqualität assoziiert 2023 ·Zeitschrift für Gastroenterologie ·L. S. Wagner, H. Schneider, Andreas Tiede, (unknown), (unknown), (unknown), (unknown), (unknown), Katja Deterding, Heiner Wedemeyer, (unknown), Benjamin Maasoumy	1
7	Poor clinical and virological outcome of nucleos(t)ide analogue monotherapy in HBV/HDV co-infected patients 2021 ·Medicine ·(unknown), (unknown), Olympia E. Anastasiou, Ulf Dittmer, Alişan Kahraman, Heiner Wedemeyer, Katja Deterding	10
8	Imprint of unconventional T‐cell response in acute hepatitis C persists despite successful early antiviral treatment 2021 ·European Journal of Immunology ·Yanqin Du, (unknown), Benedikt Strunz, Katja Deterding, Daniel Tödt, Norman Woller, (unknown), Svenja Hardtke, Kerstin Port, Andrea Ponzetta, Eike Steinmann, Markus Cornberg, Julia Hengst, Niklas K. Björkström, Heiner Wedemeyer, (unknown)	10
9	Chronic hepatitis C virus infection irreversibly impacts human natural killer cell repertoire diversity 2018 ·Nature Communications ·Benedikt Strunz, Julia Hengst, Katja Deterding, Michael P. Manns, Markus Cornberg, Hans‐Gustaf Ljunggren, Heiner Wedemeyer, Niklas K. Björkström	64
10	Aktuelle Arzneimitteltherapie der Hepatitis C 2018 ·Der Internist ·Katja Deterding, Michael P. Manns, Heiner Wedemeyer	0
11	Human γδ T Cell Receptor Repertoires in Peripheral Blood Remain Stable Despite Clearance of Persistent Hepatitis C Virus Infection by Direct-Acting Antiviral Drug Therapy 2018 ·Frontiers in Immunology ·Sarina Ravens, Julia Hengst, (unknown), Katja Deterding, Akshay Dhingra, Christian Schultze‐Florey, Christian Koenecke, Markus Cornberg, Heiner Wedemeyer, Immo Prinz	25
12	Long‐term changes in liver elasticity in hepatitis C virus‐infected patients with sustained virologic response after treatment with direct‐acting antivirals 2018 ·United European Gastroenterology Journal ·(unknown), Katja Deterding, Dina Attia, Kristina I. Ringe, Benjamin Heidrich, Markus Cornberg, M Gebel, Michael P. Manns, Heiner Wedemeyer, Andrej Potthoff	27
13	Interferon‐free therapy of chronic hepatitis C with direct‐acting antivirals does not change the short‐term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis 2017 ·Alimentary Pharmacology & Therapeutics ·(unknown), Bernhard Schlevogt, Katja Deterding, Anika Wranke, (unknown), Kerstin Port, M P Manns, Arndt Vogel, Markus Cornberg, Heiner Wedemeyer	54
14	Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens 2016 ·Journal of Hepatology ·Benjamin Maasoumy, Johannes Vermehren, Martin‐Walter Welker, Birgit Bremer, D. Perner, Christoph Höner zu Siederdissen, Katja Deterding, Patrick Lehmann, Gavin Cloherty, (unknown), Jean–Michel Pawlotsky, Michael P. Manns, Stefan Zeuzem, Markus Cornberg, Heiner Wedemeyer, Christoph Sarrazin	53
15	Improvement of liver function parameters in advanced HCV ‐associated liver cirrhosis by IFN ‐free antiviral therapies 2015 ·Alimentary Pharmacology & Therapeutics ·Katja Deterding, Christoph Höner zu Siederdissen, Kerstin Port, Philipp Solbach, (unknown), J. Kirschner, Carola Mix, (unknown), (unknown), Heiko Mix, Michael P. Manns, Markus Cornberg, Heiner Wedemeyer	87
16	Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-γ-induced protein 10 levels in HBV/HCV-coinfected patients 2015 ·Clinical Microbiology and Infection ·Steffen B. Wiegand, Jerzy Jaroszewicz, Andrej Potthoff, Christoph Höner zu Siederdissen, Benjamin Maasoumy, Katja Deterding, Michael P. Manns, Heiner Wedemeyer, Markus Cornberg	40
17	Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort 2015 ·Journal of Viral Hepatitis ·Joseph Doyle, Katja Deterding, Jason Grebely, H. Wedemeyer, Rachel Sacks‐Davis, Tim Spelman, Gail Matthews, Thomas Rice, Meghan D. Morris, Barbara McGovern, Arthur Y Kim, Julie Bruneau, Andrew R. Lloyd, Kimberly Page, Michael P. Manns, Margaret Hellard, Gregory J. Dore	8
18	Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D 2015 ·Clinical Microbiology and Infection ·Benjamin Maasoumy, Steffen B. Wiegand, Jerzy Jaroszewicz, Birgit Bremer, Patrick Lehmann, Katja Deterding, A Taranta, Michael P. Manns, Heiner Wedemeyer, Dieter Glebe, Markus Cornberg	111
19	Antiviral effect of entecavir in chronic hepatitis B: Influence of prior exposure to nucleos(t)ide analogues 2010 ·Journal of Hepatology ·Jurriën G.P. Reijnders, Katja Deterding, Jörg Petersen, Fabien Zoulim, Teresa Santantonio, Marı́a Buti, Florian van Bömmel, Bettina E. Hansen, Heiner Wedemeyer, Harry L.A. Janssen	85
20	333 KINETICS OF HCV CORE ANTIGEN DURING ANTIVIRAL TREATMENT OF ACUTE AND CHRONIC HEPATITIS C AS DETERMINED BY A NOVEL CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY 2009 ·Journal of Hepatology ·Ingmar Mederacke, Sandra Ciesek, R. Raupach, Karsten Wursthorn, Katja Deterding, Eike Steinmann, Markus Cornberg, Elmar Jaeckel, M.P. Manns, Thomas Pietschmann, Hans L. Tillmann, Heiner Wedemeyer	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact